NEURITIN:novel RGC neurotrophic factor and potential target for glaucoma therapy
NEURITIN:novel RGC neurotrophic factor and potential target for glaucoma therapy
批准号:
7895521
负责人:
Donald J. Zack
金额:
$36.39万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-08-01 至 2012-07-31
关键词:
AdultAnimal ModelAnimalsApoptosisAxonAxotomyBlindnessBrainCell DeathCell SurvivalCellsComplementCyclic GMPCyclic GMP-Dependent Protein KinasesDataDependovirusDevelopmentDiseaseDown-RegulationExperimental ModelsEyeGene ExpressionGene Expression AlterationGene TransferGenesGlaucomaGoalsGrowthHealthHumanIn Situ HybridizationIn VitroLibrariesMaintenanceMediatingModelingMolecularMusNerve CrushNeuritesOptic NerveOptic Nerve InjuriesPathogenesisPathway interactionsPhosphotransferasesPhysiologic Intraocular PressurePhysiologicalPredispositionProteinsRNA InterferenceRattusRetinaRetinal Ganglion CellsRisk FactorsRoleSignal PathwaySignal TransductionSmall Interfering RNAStressTestingTherapeuticTherapeutic StudiesTimeUnited StatesWorkaxon regenerationbasecell injurychemical geneticsdesignhigh throughput screeningin vivoinhibitor/antagonistinsightkinase inhibitorneuroprotectionneurotrophic factornew therapeutic targetnovelnovel therapeutic interventionoptic nerve disorderoverexpressionpressurepublic health relevanceresearch studytranscription factortreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Glaucoma is the second leading cause of blindness in the United States. Understanding how retinal ganglion cell (RGC) susceptibility to degeneration is modulated by the major risk factor, elevation of intraocular pressure (IOP), as well as other factors, will help in designing novel therapeutic approaches to complement IOP lowering. By studying experimental models of glaucoma and optic nerve injury, we and others have determined some of the cellular and gene expression alterations associated with the pathogenesis of glaucomatous RGC death. Among the genes whose expression is dysregulated, Neuritin1 (Nrn1) encodes a secreted factor that possesses strong neuroprotective and neurite-promoting activities on RGCs. We hypothesize that NRN1 is a novel RGC-derived neurotrophic factor whose IOP elevation- triggered downregulation in RGCs is associated with the onset and progression of RGC death in glaucoma. In this study, the therapeutic value of Nrn1 in RGC neuroprotection and axon regeneration will be evaluated with animal models of optic nerve stress. In aim1, we will assess whether Nrn1 is required for the maintenance of adult RGCs and their axonal network, whether Nrn1 can protect RGC from IOP elevation- induced degeneration, and whether it can promote RGC axon regeneration when the optic nerve is damaged. In aim2, we will focus on elucidating how Nrn1 expression is regulated by upstream signal pathway(s) and transcription factors. Moreover, the importance of these regulatory mechanisms in maintaining RGC survival will be evaluated. In aim3, we will explore the involvement of specific kinase(s) in the signal transduction of NRN1 in RGCs. By accomplishing the above proposed studies, we hope to gain insight into how impaired Nrn1 expression contributes to RGC degeneration and whether NRN1 could serve as a target for the development of novel neuroprotective strategies for the treatment of glaucoma and other optic neuropathies. PUBLIC HEALTH RELEVANCE: The goal of this project is to understand how retinal ganglion cells, the cells in the eye that transmit information from the eye to the brain, die in the disease glaucoma. We will specifically focus on the factor neuritin-1. Understanding neuritin-1's role in glaucoma may provide insights into the mechanisms of the disease, and may help to develop new treatment approaches to complement the traditional approach of eye pressure lowering.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of OPA1 in Retinal Ganglion Cell Differentiation and the Pathogenesis of Dominant Optic Atrophy
-
批准号:10705002
-
项目类别:
-
资助金额:$40.94万
-
财政年份:2022
-
负责人:Donald J. Zack
-
依托单位:
AMD THERAPY: A Screen for Molecules that Promote RPE Survival and Differentiation
-
批准号:8703116
-
项目类别:
-
资助金额:$23.81万
-
财政年份:2013
-
负责人:Donald J. Zack
-
依托单位:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
-
批准号:9127253
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2013
-
负责人:Donald J. Zack
-
依托单位:
AMD THERAPY: A Screen for Molecules that Promote RPE Survival and Differentiation
-
批准号:8575156
-
项目类别:
-
资助金额:$20.25万
-
财政年份:2013
-
负责人:Donald J. Zack
-
依托单位:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
-
批准号:8573119
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2013
-
负责人:Donald J. Zack
-
依托单位:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
-
批准号:8925084
-
项目类别:
-
资助金额:$39.69万
-
财政年份:2013
-
负责人:Donald J. Zack
-
依托单位:
Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell Injury
-
批准号:8725166
-
项目类别:
-
资助金额:$39.69万
-
财政年份:2013
-
负责人:Donald J. Zack
-
依托单位:
Protein kinase inhibitors that promote RGC survival and function
-
批准号:7934529
-
项目类别:
-
资助金额:$24.35万
-
财政年份:2009
-
负责人:Donald J. Zack
-
依托单位:
Protein kinase inhibitors that promote RGC survival and function
-
批准号:7706852
-
项目类别:
-
资助金额:$20.5万
-
财政年份:2009
-
负责人:Donald J. Zack
-
依托单位:
NEURITIN:novel RGC neurotrophic factor and potential target for glaucoma therapy
-
批准号:7565586
-
项目类别:
-
资助金额:$36.9万
-
财政年份:2009
-
负责人:Donald J. Zack
-
依托单位:
Novel Factors Promoting Retinal Ganglion Cell Growth
-
批准号:7026572
-
项目类别:
-
资助金额:$20.43万
-
财政年份:2006
-
负责人:Donald J. Zack
-
依托单位:
Novel Factors Promoting Retinal Ganglion Cell Growth
-
批准号:7244061
-
项目类别:
-
资助金额:$23.88万
-
财政年份:2006
-
负责人:Donald J. Zack
-
依托单位:
CORE--BIOINFORMATICS
-
批准号:6993155
-
项目类别:
-
资助金额:$16.39万
-
财政年份:2004
-
负责人:Donald J. Zack
-
依托单位:
ANALYSIS OF HUMAN VMD2: A MODEL FOR RPE GENE REGULATION
-
批准号:6498571
-
项目类别:
-
资助金额:$50.48万
-
财政年份:2001
-
负责人:Donald J. Zack
-
依托单位:
ANALYSIS OF HUMAN VMD2: A MODEL FOR RPE GENE REGULATION
-
批准号:6803922
-
项目类别:
-
资助金额:$36.79万
-
财政年份:2001
-
负责人:Donald J. Zack
-
依托单位:
ANALYSIS OF HUMAN VMD2: A MODEL FOR RPE GENE REGULATION
-
批准号:6662401
-
项目类别:
-
资助金额:$38.95万
-
财政年份:2001
-
负责人:Donald J. Zack
-
依托单位:
ANALYSIS OF HUMAN VMD2: A MODEL FOR RPE GENE REGULATION
-
批准号:6650715
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2001
-
负责人:Donald J. Zack
-
依托单位:
ANALYSIS OF HUMAN VMD2: A MODEL FOR RPE GENE REGULATION
-
批准号:6459379
-
项目类别:
-
资助金额:$17.22万
-
财政年份:2001
-
负责人:Donald J. Zack
-
依托单位:
ANALYSIS OF HUMAN VMD2: A MODEL FOR RPE GENE REGULATION
-
批准号:6299071
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2001
-
负责人:Donald J. Zack
-
依托单位:
P30 Wilmer Core Grant for Vision Research
-
批准号:8745026
-
项目类别:
-
资助金额:$81.0万
-
财政年份:1997
-
负责人:Donald J. Zack
-
依托单位:
海外基金